Why did Melexis drag the Brussels stock market lower?

Melexis shares tumbled 7.13% to €72.30 on Euronext Brussels

Place

Brussels

City where Melexis shares trade and the BEL 20 market impact was recorded.

Why it matters

City where Melexis shares trade and the BEL 20 market impact was recorded.

About

The City of Brussels is the largest municipality and historical centre of the Brussels-Capital Region, as well as the capital of the French Community of Belgium, the Flemish Region, and Belgium. The City of Brussels is also the administrative centre of the European Union, as it hosts a number of principal EU institutions in its European Quarter.

Official site ↗View source record ↗

The immediate trigger was an analyst decision rather than a profit warning, factory disruption or cancelled order. Deutsche Bank analyst Robert Sanders lowered the recommendation on Melexis from “buy” to “hold”, although he simultaneously raised his price target from €65 to €75. Reporting carried by Boursorama and Investing.com said the bank’s broader technology-hardware review highlighted risks including uncertain returns on artificial-intelligence spending, possible double ordering of components and the prospect of weaker capital expenditure by large data-centre operators.

That reasoning requires some care in Melexis’s case. The company is not chiefly a supplier of processors for generative-AI systems. Founded in Belgium and listed under ticker MELE, with ISIN BE0165385973, Melexis designs sensors and mixed-signal chips used largely in vehicles. Its products measure such things as temperature, pressure, position and current, allowing electronic systems to control braking, steering, batteries, motors and cabin functions. The company’s later second-quarter statement showed that automotive applications generated 89% of sales, underlining how closely its fortunes remain tied to vehicle production and the rising semiconductor content of each car.

The downgrade nevertheless landed after a strong run. Investing.com calculated that the shares had risen roughly 39% over the preceding three months. With Melexis trading close to Deutsche Bank’s new €75 target before the downgrade, investors were being told that much of the expected improvement was already reflected in the price. The result was rapid profit-taking: historical quotations show turnover of about 101,000 shares on 10 July, against roughly 26,000 the previous session, while the closing price fell from €77.85 to €72.30.

Melexis was not the Brussels market’s only problem that day. Pharmaceutical groups UCB and Argenx dropped 5.16% and 4.14% respectively, while steelmaker Aperam gained 4.31%. Across the exchange, advancing shares narrowly outnumbered decliners, but large losses among BEL 20 constituents outweighed that broader resilience. This is how one relatively compact group of heavily weighted companies can make the headline index look considerably weaker than the average Brussels-listed share.

The move also came during an unsettled week for European markets. Belgian consumer organisation Testachats Invest said the BEL 20 lost 2.9% over the week, compared with a 1.7% fall for the Stoxx Europe 50, amid renewed geopolitical and inflation concerns and volatile trading in technology stocks. Melexis finished that week about 8% lower. Its decline therefore combined a company-specific reassessment with a market already inclined to reduce risk.

The subsequent operating figures provide an important counterweight to the market reaction. On 29 July, Melexis reported second-quarter revenue of €217.1 million, 3% higher than a year earlier and 7% above the first quarter. Operating profit rose 8% year on year to €38.6 million, with an operating margin of 17.8%. Net profit, however, fell 19% to €30.8 million, partly illustrating why investors were still distinguishing between improving sales and the earnings ultimately available to shareholders.

For the first half, revenue reached €419.2 million, 2% above the corresponding 2025 period, while net profit declined 14% to €53.9 million. Melexis said steering and braking products and thermal-management applications performed particularly well. It forecast third-quarter sales of €220 million to €225 million and second-half revenue of €445 million to €455 million, with an operating margin around 18%. Those figures suggest recovery rather than a sudden collapse in underlying demand, but they do not eliminate the automotive cycle, currency exposure or pressure on customers’ inventories.

For Belgian households, the episode has little direct bearing on an energy bill, payslip or mortgage rate. Its concrete effects run mainly through investments: Melexis is held by individual shareholders, pension vehicles and funds tracking Belgian equities, so a sharp fall reduces portfolio values and can weigh on BEL 20-linked products. The lesson is also relevant to savers who treat a national index as broadly diversified. Brussels contains internationally exposed companies whose daily prices may react to global technology spending, vehicle demand, currencies and analyst research rather than to Belgian consumer conditions.

For businesses, Melexis matters as part of Belgium’s unusually deep semiconductor ecosystem, alongside Leuven

Place

Leuven

City hosting imec and a major part of Belgium’s semiconductor research ecosystem.

Why it matters

City hosting imec and a major part of Belgium’s semiconductor research ecosystem.

About

Leuven, also called Louvain, is the capital and largest city of the province of Flemish Brabant in the Flemish Region of Belgium. A Dutch-speaking municipality, it is located about 25 kilometres east of Brussels. The municipality itself comprises the sub-municipalities of Heverlee, Kessel-Lo, Leuven proper, Wilsele, and Wijgmaal and parts of Haasrode and Korbeek-Lo. It is the eighth largest city in Belgium, with more than 100,244 inhabitants.

Official site ↗View source record ↗

Two interpretations therefore coexist. Momentum-focused investors can reasonably view the downgrade and the limited distance to Deutsche Bank’s price target as a warning that expectations had outrun near-term earnings. Longer-term industrial investors can point to increasing chip content per vehicle, Melexis’s second-quarter sales growth and improved operating margin as evidence that the company’s core franchise remained intact. Neither position turns an analyst target into a certainty; it is an estimate, not a promise of where the shares will trade.

Attention now shifts from the dramatic July session to execution. Investors will compare Melexis’s third-quarter sales with its €220 million-to-€225 million guidance, examine whether the gross margin approaches the projected 41% in the second half and watch inventories across the automotive supply chain. Currency movements also matter because Melexis said the euro-dollar exchange rate reduced first-half revenue growth by two percentage points. The share-price fall revealed less about a sudden failure at a Belgian manufacturer than about how quickly markets can reprice a good company when valuation, sector anxiety and a prominent analyst downgrade arrive together.